Compare NATL & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | BLLN |
|---|---|---|
| Founded | 2023 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.9B |
| IPO Year | 2023 | N/A |
| Metric | NATL | BLLN |
|---|---|---|
| Price | $43.48 | $107.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $45.60 | ★ $126.71 |
| AVG Volume (30 Days) | 492.7K | ★ 758.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.98 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $4,354,000,000.00 | N/A |
| Revenue This Year | $6.13 | $46.29 |
| Revenue Next Year | $4.24 | $30.14 |
| P/E Ratio | $150.28 | ★ N/A |
| Revenue Growth | ★ 0.86 | N/A |
| 52 Week Low | $23.56 | $61.96 |
| 52 Week High | $48.50 | $138.70 |
| Indicator | NATL | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 62.05 |
| Support Level | $42.20 | $79.07 |
| Resistance Level | $46.00 | $138.70 |
| Average True Range (ATR) | 0.54 | 7.52 |
| MACD | -0.08 | 0.37 |
| Stochastic Oscillator | 22.85 | 92.85 |
NCR Atleos Corp is a financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers, and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels, all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware, and its proprietary Allpoint network. Atleos manages its operations in the following segments: Self-Service Banking, which generates maximum revenue, Network, and Telecommunications and Technology. Geographically, it derives maximum revenue from the U.S.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.